Pfizer Ireland is Overall Winner of ISPE’s 2014 Facility of the Year Award

The International Society for Pharmaceutical Engineers (ISPE) announced Pfizer Ireland Pharmaceuticals as the 2014 Facility of the Year Awards (FOYA) Overall Winner.

Pfizer Ireland's Network Strategy Implementation (NSI) Expansion Capacity project challenged the company to add capacity by re-purposing an existing manufacturing space for a new vaccine suite and a new multiproduct small-to-medium scale drug substance bioprocess suite at the Grange Castle plant in Clondalkin, South County Dublin.

"The NSI Expansion Capacity project exemplified the mission of FOYA," said ISPE President and CEO John Bournas. "Pfizer Ireland's vision of empowerment and operational excellence enabled the company to produce a world-class manufacturing environment and expand the capacity of its biotech operations on an aggressive timeline."

Throughout the project, Pfizer Ireland utilized a Lean Management Strategy and a 5S program in the design process to ensure flow and operations. Additionally, a Six Sigma toolkit was developed for all project personnel, and all production processes were value stream-mapped. The project team also ensured the new manufacturing suites included the latest technologies (i.e. EBR, PAT and Disposable Bag).

"We are excited to recognize Pfizer Ireland as an innovator in operational excellence," said Chair of the FOYA Judging Panel James Breen, "The society was impressed with the NSI Capacity Expansion project and the company's ability to effectively manage the challenges of maintaining supply with the demolition of existing facilities, new construction, and start-up and integration activities."

Celebrating its tenth year, FOYA continues to showcase the pharmaceutical manufacturing industry's accomplishments in facility design, construction and operation, while sharing the development of new applications of technology and cutting-edge approaches.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

ProteiNext 2025

ProteiNext 2025

ProteiNext is an annual symposium that offers a platform for sharing insights on protein analysis

most read

Photo
19.03.2025 • TopicsChemistry

Making Waves

Global water scarcity is now urgent due to climate change, population growth, and unsustainable practices. 700 million people could be displaced by 2030, warns UNICEF, especially in water-intensive industries like personal care, textiles, food production, and paint.

Photo
19.03.2025 • TopicsDigitalization

From Data Silos to a Digital Future

Chemical producers in Germany are grappling with rising costs, high energy prices, global competition, and an impending knowledge gap due to demographic shifts. Kuraray, a global leader in specialty chemicals, is addressing these challenges with a comprehensive digitalization strategy.

Photo
19.03.2025 • TopicsStrategy

Substances of Concern

The EU Chemicals Strategy for Sustainability (CSS) highlights the shift to a hazard-centric approach in EU chemical regulation, emphasizing 'Substance of Concern' over risk-based measures.

Photo
11.11.2024 • TopicsDigitalization

Artificial Intelligence – a Revolution for Innovation?

Artificial intelligence (AI) has made groundbreaking progress in recent years, particularly through innovations in machine learning and neural networks. These developments are largely driven by deep learning technologies, which enable the recognition of complex data patterns and the achievement of human-like performance in areas such as speech recognition, image processing, and decision-making.